1. Gregory Dolganov
San Carlos, CA94070
Cell Phone: 650-533-2545
g.dolganov@comcast.net; gregoryd@stanford.edu
------------------------------------------------------------------------------------------------------------------------------------------
Summary. Experienced leader in Molecular diagnostics, Biomarker development, Gene expression Analysis and
Multiplex PCR, wired for innovation and Next-Gen Molecular technologies. MD PhD in Molecular Biology with
extensive experience and focus on innovation technologies for clinical research and life-scienceapplications. During
the last 20 years at Genelabs, UCSF and Stanford developed high Multiplex qRT-PCR gene expression platform for
interrogation of disease-associated genes in small clinical specimens,laser captured/flow-sorted cells,and pathogen
infected clinical specimens.Later atStanford,with FundingfromGates Foundation designed and developed accurate
and sensitive Mtb gene expression profiling in high background of host DNA and RNA. In collaboration with peers
from Broad Institute, Boston University, and other collaborators elsewhere, developed a suite of tools for
multiplatformanalysis of TB-infected clinical specimens.Multipletranscriptomics,proteomics,glycomics,lipidomics
and metabolomics measurements have been obtained of Mtb and of the Mtb-infected host cell and published in
Nature (2013).This very sensitiveand specific assay and the correspondingstatistical and bioinformaticstools have
been extensively used and validated.Actively participated in Translational Research and Applied MedicineProgram
at Stanford. Currently, a high-throughput and highly multiplex assay for point of care diagnostics of Mtb is being
developed under my supervision on Hydra1K platformchosen through growing research collaboration with a small
Silicon Valley start-up InSilixa,founded by academic semi-conductor engineers from Stanford. Since2014 I assumed
the role of Director of Assay Development at InSilixa.Currently I amlookingforward new challenges with hope that
my energy, enthusiasmand my extensive expertise and networking capabilities will makean impacton global health
via development and promotion of novel POC diagnostic platforms. Consulted Cellecta on their new DriverMap
technology and currently involved in the design of new NGS-based gene expression profiling platform for MTB-
infected clinical specimens thatcould be also used as companion assay in drugdevelopment and diagnostics.
2014 – 2016 Director of Research and Development at InSilixa.
Director of Assay Development (collaboration between Stanford and Insilixa) working on POC MDx platform for
Diagnostics of MDR/XDR TB that is based on: (1) Multiplex qPCR, (2) hybridization to cMOS oligonucleotide microarrays
(32x32 biosensors) followed by (3) HR Melt Curve Analysis for detecting Drug Resistant SNPs on the surface of the chip
(current throughput is over 250 SNPs). This platform can be used for POC MDx applications to any pathogen, or even a
host. This could revolutionize translational medicine and bring MDX from bench to bedside to community. This MDx
platform may eventually become a drug companion assay to improve drug screening and help to select drugs for custom
treatment of patients.
2006 - present Senior Research Scientist, Division of Infectious Diseases,Stanford University
Developed Multiplex qRT-PCR for genome-wide gene expression profiling of TB-infected
clinical specimens to study immunopathogenesis of TB in natural human/animal hosts
during the infection, including persistence, or reactivation from latency. Designed more
the than 2,500 assays for MTB genes distinguishing between various strains of TB in
clinical cohorts specimens.

2. 2000 – 2006 Assistant Professor of Medicine, Department of Medicine,Division of Pulmonary and Critical
Care Medicine,
UCSF, San Francisco.
 Developed a strategy for identifying disease gene targets based on differential gene
expression analyses in healthy vs. diseased tissues, and functional gene inactivation.
Optimized multiplex real time PCR for gene expression profiling in individual laser-captured
cells from airway submucosa.
 Initiated collaborations with PI’s at UCSF, Stanford, Harvard and Primate Research Center at
UC Davis on a number of clinical research projects including asthma, COPD and CF. Used
transcriptional profiling on purified populations of submucosal gland and airway surface
epithelial cells from COPD and CF specimens.
 With peers at UCSF validated direct effects of interleukin-13 on epithelial cells that causes
airway hyper reactivity and mucus overproduction in asthma.
 Involved in functional studies on cancer targets including members of EGF, BMP and TFG
families in the smokers vs. healthy subjects in asthma and COPD.
 Co-founder of Bi-Par Sciences, Inc. acquired by Sanofi-Aventis in 2009.
Other Experience and Professional Memberships
Co-founder: Bi-PARPharmaceuticals(2002)
 American Association for theAdvancementof Sciences
 American Society for Human Genetics.
PATENTS:
US 4,680,260 (July 14, 1987) Method for producinghuman leukocyte interferon alpha-2 Vladimir GDebabov, et al.
US 4,988,622 (January 29, 1991) Recombinant plasmid DNA pVN 22 coding biosynthesis of human leukocyte
interferon alpha-I1 and strain Pseudomonas sp. 31 (pVN 22) - producer of human leukocyte interferon alpha-I1
containingsameVladimir GDebabov, et al.
US 5,965,427 (October 13, 1998) Transcripts encodingimmunomodulatory polypeptides Dolganov; Gregory (Menlo
Park,CA) - Genelabs Technologies, Inc. (Redwood City, CA).
US 5,821,091(October 13, 1998) Human RAD50 gene and methods of use thereof Dolganov; Gregory (San Carlos,
CA); Novikov; Alexander (Foster City, CA) - Genelabs Technologies, Inc. (Redwood City, CA).
US 5,821,091 (October 12, 1999) Method of identifying activated T-cells Dolganov; Gregory (Menlo Park, CA) -
Genelabs Technologies, Inc. (Redwood City, CA).
Representative Publications:
1. G. M. Dolganov, P.G. Woodruff,A. Novikov, Y. Zhang, R. E. Ferrando,R. Szubin and J.V. Fahy. (2001) A novel
method of gene transcript profiling in airway biopsy homogenates reveals increased expression of a Na +-
K+-Cl- cotransporter (NKCC1) in asthmatic subjects. Genome Research 11(9): 1473-1483.

3. 2. D.A. Kuperman, X. Huang, L.L. Koth, G. H. Chang, G. M. Dolganov, Z. Zhu, J.A. Elias,D. Sheppard & D.J. Erle
(2002) Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus
overproduction in asthma. Nat. Med. 8 (8): 885-9.
3. DG. Morris,N. Kaminski, X.Huang,SD. Shapiro, G.Dolganov -
mediated TGF-beta activation causes MMP-12-dependent emphysema. Nature 422 (6928):169-173
4. Schnappinger, D., Ehrt, S., Voskuil, M. I., Liu, Y., Mangan, J. A., Monahan, I. M., Dolganov, G., Efron, B.,
Butcher, P. D. Nathan, C., and Schoolnik, G. K. (2003) Transcriptional Adaptation of Mycobacterium
tuberculosis within Macrophages:Insights into thePhagosomal Environment.JExp Med.198(5):p. 693-704.
5. Voskuil,M.I.,Schnappinger,D., Visconti,K.C.,Harrell,M.I., Dolganov, G. M., Sherman, D. R., and Schoolnik,
G. K. (2003) Inhibition of Respiration by Nitric Oxide Induces a Mycobacterium tuberculosis Dormancy
Program. J Exp Med. 198(5): 705-13.
6. Voice J, Donnelly S, Dorsam G, Dolganov G, Paul S, Goetzl EJ. (2004) c-Maf and JunB mediation of Th2
differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactiveintestinal peptide.
J Immunol. 172(12): 7289-96.
7. Aurora, A. B., P. Baluk, Zhang, D., Sidhu, S. S., Dolganov, G. M., Basbaum, C., McDonald,D. M., Killeen,N.
(2005). "Immune complex-dependent remodeling of the airway vasculature in response to a chronic
bacterial infection."JImmunol 175(10): 6319-26.
8. Barker, C. S., C. Griffin, Dolganov, G. M., Hanspers, K., Yang, J. Y., Erle, D. J. (2005) "Increased DNA
microarray hybridization specificity usingsscDNAtargets." BMC Genomics 6(1): 57.
9. Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, Ellwanger A, Sidhu SS, Dao-Pick
TP, Pantoja C,Erle DJ, Yamamoto KR, Fahy JV (2007) “Genome-wide profilingidentifies epithelial cell genes
associated with asthma and with treatment response to corticosteroids.” Proc Natl Acad Sci U S A.
104(40):15858-63
10. Lopez-Souza N, Favoreto S, Wong H, Ward T, Yagi S, Schnurr D, Finkbeiner WE, Dolganov GM, Widdicombe
JH, Boushey HA, Avila PC (2009) In vitro susceptibility to rhinovirus infection is greater for bronchial than
for nasal airway epithelial cellsin human subjects. JAllergy Clin Immunol. 123(6):1384-90
11. Aagaard,C, Hoang T, Dietrich J, Cardona PJ, Dolganov G, Schoolnik,GK, Cassidy JP,Billeskov R,Andersen P.
(2011) A multi-stage tuberculosis vaccine that confers efficient protection before and after exposure. Nat.
Med. 17: 189-194
12. Marmai C, Sutherland RE, Kim KK, Dolganov GM, Fang X, Kim SS, JiangS, Golden JA, Hoopes CW, Matthay
MA, Chapman HA, Wolters PJ (2011) Alveolar epithelial cellsexpress mesenchymal proteins in patients with
idiopathic pulmonary fibrosis.Am J Physiol LungCell Mol Physiol 301:L71-78.
13. McGuire AM, Weiner B, Park ST, Wapinski I,Raman S, Dolganov G, Peterson M, Riley R, Zucker J, Abeel T,
White J, Sisk P, Stolte C, Koehrsen M, Yamamoto RT, Iacobelli-Martinez M, Kidd MJ, Maer AM, Schoolnik
GK, Regev A, Galagan J (2012) Comparative analysis of Mycobacterium and related Actinomycetes yields
insightinto the evolution of Mycobacterium tuberculosis pathogenesis.BMC Genomics 13:120.
14. Commandeur S,van Meijgaarden KE,Prins C,Pichugin AV,Dijkman K,van den Eeden SJ, Friggen AH, Franken
KL, Dolganov G, Kramnik I,Schoolnik GK,Oftung F, Korsvold GE, Geluk A, Ottenhoff TH. (2013) An unbiased
genome-wide Mycobacterium tuberculosis gene expression approach to discover antigens targeted by
human T cells expressed duringpulmonary infection. J Immunol. 190(4):1659-71.

4. 15. Galagan J, Dolganov G, et al. (2013) “The Mycobacterium Tuberculosis Regulatory Network and Hypoxia.”
Nature 499 (7457):178-83.
16. Hoang T, Aagaard C, Dietrich J, Cassidy JP, Dolganov G, Schoolnik GK, Lundberg CV, Agger EM, Andersen P
(2013) ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposuretuberculosis vaccination.
PLoS One 2013, 8(12):e80579.
17. Knudsen NP, Norskov-Lauritsen S, Dolganov GM, Schoolnik GK, Lindenstrom T, Andersen P, Agger EM,
Aagaard C (2014) Tuberculosis vaccine with high predicted population coverage and compatibility with
modern diagnostics.Proc Natl Acad Sci U S A 111(3):1096-1101.
18. Garcia B, Walter ND, Dolganov G, Coram M, Davis JL, Schoolnik GK, Strong M (2014) A minimum variance
method for genome-wide data-driven normalization of quantitative real-time polymerase chain reaction
expression data. Anal Biochem 458:11-13.
19. Rienksma, R. A., Suarez-Diez, M., Mollenkopf, H. J., Dolganov, G. M., Dorhoi, A., Schoolnik, G. K., Martins
Dos Santos, V. A., Kaufmann, S. H., Schaap, P. J., Gengenbacher, M. (2015) Comprehensive insights into
transcriptional adaptation of intracellular mycobacteria by microbe-enriched dual RNA sequencing. BMC
Genomics 16:34.
20. Walter ND, Dolganov GM, Garcia BJ, Worodria W, Andama A, Musisi E, Ayakaka I, Van TT, Voskuil MI, de
Jong BC, Davidson RM,Fingerlin TE, Kechris K,Palmer C, Nahid P, Daley CL, Geraci M, Huang L, Cattamanchi
A, Strong M, Schoolnik GK, Davis JL (2015) Transcriptional Adaptation of Drug-tolerant Mycobacterium
Tuberculosis DuringTreatment of Human Tuberculosis.15;212(6):990-8.
21. Ofori-AnyinamB, Kanuteh F, Agbla SC, Adetifa I, Okoi C, Dolganov G, Schoolnik G, Secka O, Antonio M, de
Jong BC, Gehre F. (2016). "Impact of the Mycobaterium africanumWestAfrica 2 Lineage on TB Diagnostics
in West Africa:Decreased Sensitivity of Rapid Identification Tests in TheGambia."PLoS Negl Trop Dis 10(7):
e0004801.
22. Walter ND, de Jong BC, Garcia BJ, Dolganov GM, Worodria W,Byanyima P, Musisi E, HuangL, Chan ED,
Van TT, Antonio M, Ayorinde A, Kato-Maeda M, Nahid P, Leung AM, Yen A, Fingerlin TE, Kechris K,Strong
M, Voskuil MI,Davis JL, Schoolnik GK. (2016) Adaptation of Mycobacteriumtuberculosis to Impaired Host
Immunity in HIV-Infected Patients.J Infect Dis.214(8):1205-11.
23. Garcia BJ,Loxton AG, Dolganov GM, Van TT, Davis JL, de Jong BC, Voskuil MI,Leach SM, Schoolnik GK,
Walzl G,Strong M, Walter ND. (2016) Sputum is a surrogate for bronchoalveolar lavagefor monitoring
Mycobacterium tuberculosis transcriptional profiles in TBpatients.Tuberculosis (Edinb).100:89-94.
24. Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, Van T, Chen RY, Warwick J, Via LE,
Song T, Lee M, Schoolnik G, Tromp G, Alland D, Barry CE 3rd, Winter J, Walzl G; Catalysis TB–Biomarker
Consortium., Lucas L, Spuy GV, Stanley K, Theart L, Smith B, Burger N, Beltran CG, Maasdorp E, Ellmann A,
Choi H, Joh J, Dodd LE, Allwood B, Kogelenberg C, Vorster M, Griffith-RichardsS.(2016) Persistingpositron
emission tomography lesion activity and Mycobacteriumtuberculosis mRNA after tuberculosis cure.Nat
Med. (10):1094-1100.
25. Coppola M, van Meijgaarden KE, Franken KL, Commandeur S, Dolganov G, Kramnik I, Schoolnik GK,Comas
I, Lund O, Prins C,van den Eeden SJ, Korsvold GE, Oftung F, Geluk A, Ottenhoff TH. (2016) New Genome-
Wide Algorithm Identifies Novel In-Vivo Expressed Mycobacterium Tuberculosis Antigens InducingHuman
T-Cell Responses with Classical and Unconventional CytokineProfiles.Sci Rep. 6:37793.